Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Benign and Malignant Neoplasms of the Head and Neck
share announcement

Benign and Malignant Neoplasms of the Head and Neck

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 15 November 2025 | Viewed by 4909

Special Issue Editors

Dr. Charles C. L. Tong

E-Mail Website
Guest Editor
Department of Otolaryngology-Head and Neck Surgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA
Interests: sinonasal and skull base tumor; inverted papilloma; squamous cell carcinoma
Dr. Brett A. Miles

E-Mail Website
Guest Editor
Department of Otolaryngology-Head and Neck Surgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA
Interests: head and neck cancer; HPV; salivary gland tumors; base of tongue cancer; robotic surgery

Special Issue Information

Dear Colleagues,

Head and neck tumors are a diverse group of neoplasms that present significant diagnostic and therapeutic challenges. This Special Issue focuses on benign and malignant head and neck tumors, exploring their pathogenesis, novel treatment options, specific biomarkers and therapeutic targets to improve diagnostics and treatment. 

This Special Issue will cover various topics relating head and neck neoplasms. We welcome submissions on the following subtopics: 

  • Research outcomes in disease control and overall survival in head and neck tumors;
  • Novel surgical techniques;
  • Novel biomarkers and potential therapeutic targets;
  • Advances in diagnostic tools, imaging protocols, AR/VR-assisted surgical planning;
  • Quality of life outcomes (cosmesis, voice, swallowing and hearing preservation).

Other topics within the scope of the issue will also be considered. We look forward to your contributions. 

Dr. Charles C. L. Tong
Dr. Brett A. Miles
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • laryngeal cancer
  • oral cavity and oropharynx cancer
  • nasal cavity and paransal sinus cancer
  • anterior and lateral skull base cancer
  • salivary gland cancer
  • melanoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1162 KiB  
Article
Oncologic Outcomes in Patients with Localized, Primary Head and Neck Synovial Sarcoma
by Riddhi R. Patel, Vancheswaran Gopalakrishnan, Behrang Amini, Alexander J. Lazar, Patrick P. Lin, Robert S. Benjamin, Andrew J. Bishop, Ryan P. Goepfert and Dejka M. Araujo
Cancers 2024, 16(23), 4119; https://doi.org/10.3390/cancers16234119 - 9 Dec 2024
Viewed by 1132
Abstract
Background: this study aims to evaluate the survival outcomes of patients suffering from head and neck synovial sarcoma (HNSS), especially in relation to patients with a localized disease at diagnosis. Methods: this retrospective chart review includes 57 patients diagnosed with primary HNSS between [...] Read more.
Background: this study aims to evaluate the survival outcomes of patients suffering from head and neck synovial sarcoma (HNSS), especially in relation to patients with a localized disease at diagnosis. Methods: this retrospective chart review includes 57 patients diagnosed with primary HNSS between 1981 and 2020 who presented with a localized disease at diagnosis. Overall survival (OS) from diagnosis, local recurrence-free survival (LRFS), and metastasis-free survival (MFS) from the end of the primary tumor treatment are estimated. The Kaplan–Meier method, the log-rank test, and the Cox proportional hazards regression are used. Results: the 5-year OS, LRFS, and MFS are estimated at 80.4% (95% CI: 66.6%, 88.9%), 67.7% (95% CI: 50.0%, 80.4%), and 50.6% (95% CI: 34.4%, 64.8), respectively. Compared to patients undergoing surgical resection alone, those receiving radiation therapy (RT) with surgery have better LRFS (HR: 0.03, 95% CI: 0.001, 0.57), and those undergoing neo/adjuvant chemotherapy with surgery and RT have better MFS (HR: 0.10, 95% CI: 0.01, 0.95). Moreover, among the patients with tumors ≥ 4 cm, those subject to neo/adjuvant chemotherapy have significantly better MFS (5-year MFS: 53.2%, 95% CI: 29.0%, 72.5%) than those treated with surgery and RT alone (5-year MFS: 20.0%, 95% CI: 0.8%, 58.2%) (LR-p = 0.003). Conclusions: overall, the prognosis of HNSS patients looks favorable. Perioperative RT significantly improves local control, and perioperative chemotherapy plays a vital role in delaying metastasis formation in patients with primary HNSS when diagnosed with a localized disease. Importantly, we recommend that systemic therapy should be considered for HNSS patients with tumors ≥ 4 cm. Full article
(This article belongs to the Special Issue Benign and Malignant Neoplasms of the Head and Neck)
►▼ Show Figures

Figure 1

20 pages, 8018 KiB  
Article
Morphological and Immunohistochemical Aspects with Prognostic Implications and Therapeutic Targets of Primary Sinonasal Mucosal Melanoma: A Retrospective Study
by Cornelia Marina Trandafir, Raluca Maria Closca, Marioara Poenaru, Oana Silvana Sarau, Cristian Andrei Sarau, Marina Rakitovan, Flavia Baderca and Laurentiu Vasile Sima
Cancers 2024, 16(16), 2863; https://doi.org/10.3390/cancers16162863 - 16 Aug 2024
Cited by 3 | Viewed by 1096
Abstract
Sinonasal mucosal melanoma originates from melanocytes and it is a rare malignancy in the sinonasal tract. It is an aggressive melanocytic neoplasm with a very poor prognosis. The symptoms are nonspecific and the diagnosis is delayed, usually until the advanced stages of the [...] Read more.
Sinonasal mucosal melanoma originates from melanocytes and it is a rare malignancy in the sinonasal tract. It is an aggressive melanocytic neoplasm with a very poor prognosis. The symptoms are nonspecific and the diagnosis is delayed, usually until the advanced stages of the disease. The current study performs a correlation between the histopathological aspects of sinonasal mucosal melanoma and different types of immune cells present in the microenvironment, with prognostic and therapeutic implications. The endpoint is to quantify the cellular immune microenvironment and correlate it with patient survival. This study presents nine cases of primary sinonasal mucosal melanomas diagnosed at the Emergency City Hospital Timisoara, Romania during a period of 15 years. The histopathological examination was performed in the Department of Pathology of the same hospital, using morphological hematoxylin–eosin staining. Additional immunohistochemical reactions were performed to confirm the diagnosis and evaluate the components of the tumor immune microenvironment. This study identifies eosinophils, macrophages, natural killer cells and plasma cells as favorable prognostic factors. Therefore, a CD8:CD4 ratio of more than 3 is correlated with a good response to PD-1 inhibitor therapy. Full article
(This article belongs to the Special Issue Benign and Malignant Neoplasms of the Head and Neck)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 2966 KiB  
Review
Laryngeal Papillomatosis
by Jared Levinson and William Edward Karle
Cancers 2025, 17(6), 929; https://doi.org/10.3390/cancers17060929 - 10 Mar 2025
Viewed by 1034
Abstract
Laryngeal papillomatosis and recurrent respiratory papillomatosis are caused by the human papillomavirus. It is characterized by papillomatous growths and is the most common benign disease of the larynx. Juvenile-onset RRP is characterized by more aggressive disease compared with adult-onset RRP. Patients often require [...] Read more.
Laryngeal papillomatosis and recurrent respiratory papillomatosis are caused by the human papillomavirus. It is characterized by papillomatous growths and is the most common benign disease of the larynx. Juvenile-onset RRP is characterized by more aggressive disease compared with adult-onset RRP. Patients often require frequent surgical procedures, with an increasing shift toward office-based treatment. A variety of surgical and adjuvant medical therapies are available with mixed responses. New targeted therapies and vaccines are currently under investigation as potential adjuncts in the management. Full article
(This article belongs to the Special Issue Benign and Malignant Neoplasms of the Head and Neck)
►▼ Show Figures

Figure 1

10 pages, 423 KiB  
Review
Recurrent Sinonasal Squamous Cell Carcinoma: Current Insights and Treatment Advances
by Meryl B. Kravitz, Vivek Annadata, Benjamin Ilyaev, Charles C. L. Tong, Judd H. Fastenburg and Mark B. Chaskes
Cancers 2025, 17(1), 4; https://doi.org/10.3390/cancers17010004 - 24 Dec 2024
Viewed by 962
Abstract
Squamous cell carcinoma is the most common malignancy affecting the sinonasal tract. Local recurrence is the main pattern of treatment failure, affecting nearly half of patients treated for primary sinonasal squamous cell carcinoma (SNSCC). Due to disease rarity and heterogeneity of practices, there [...] Read more.
Squamous cell carcinoma is the most common malignancy affecting the sinonasal tract. Local recurrence is the main pattern of treatment failure, affecting nearly half of patients treated for primary sinonasal squamous cell carcinoma (SNSCC). Due to disease rarity and heterogeneity of practices, there are limited guidelines for how to diagnose and care for these patients. This paper reviews current evidence regarding etiology, pathophysiology, diagnosis, prognostic factors, and treatment modalities of recurrent SNSCC (rSNSCC). Currently, salvage surgery offers the only durable approach for eligible patients. These resections often require robust reconstructive options due to prior surgery or radiation. Chemoradiation is offered as an adjuvant or palliative approach when surgery is not a feasible option. Emerging options such as immunotherapy and particle therapy remain an area of ongoing investigation. Full article
(This article belongs to the Special Issue Benign and Malignant Neoplasms of the Head and Neck)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop